07:00 , Aug 4, 2016 |  BC Innovations  |  Translation in Brief

CAR checkpoints

The next big hurdle for chimeric antigen receptor (CAR) T cell therapies is to extend their promise in blood cancers to solid tumors. The solution, according to a group at Memorial Sloan Kettering Cancer Center...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

Harvard Apparatus Regenerative management update

Harvard Apparatus Regenerative Technology Inc. (NASDAQ:HART), Holliston, Mass.   Business: Gene/Cell therapy   Hired: Saverio La Francesca, a cardiothoracic surgeon, as CMO; formerly director of the Exvivo lung perfusion laboratory at the Department of Cardiovascular...
07:00 , Apr 25, 2013 |  BC Innovations  |  Tools & Techniques

Regenerating the kidney

Researchers at Harvard Medical School and Massachusetts General Hospital have shown that their previously described platform for creating transplantable bioengineered organs from decellularized matrices can be used to create a functional kidney. 1 The researchers...
07:00 , Mar 14, 2013 |  BC Innovations  |  Tools & Techniques

VentriGel goes into pigs

Researchers at the University of California, San Diego and Ventrix Inc. have developed a catheter-compatible hydrogel that restored cardiac function in a pig model with myocardial infarction. 1 Ventrix is now scaling up manufacture of...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Clinical News

S: Phase II/III discontinued

Merck and Intercell terminated a double-blind, placebo-controlled, international Phase II/III trial of V710 after an analysis by the study's independent DMC showed that the vaccine was unlikely to demonstrate a statistically significant clinical benefit. The...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

S: Phase II/III suspended enrollment

Merck and Intercell suspended enrollment in a double-blind, placebo-controlled, international Phase II/III trial of V710 pending further analyses of the vaccine's benefit-risk profile. The decision was based on a recommendation by the study's independent DMC....
07:00 , Apr 18, 2011 |  BioCentury  |  Finance

Risk/benefit uncertainty

A potential safety signal and/or minimal efficacy are possible culprits in last week's suspension of enrollment in a Phase II/III trial of Intercell AG 's V710 to prevent Staphylococcus aureus infections. Shares of Intercell (VSE:ICLL;...
00:28 , Apr 12, 2011 |  BC Extra  |  Clinical News

Intercell falls on Staph vaccine setback

Intercell AG (VSE:ICLL; OTCQX:INRLY) fell EUR 2.32 (28%) to EUR 5.88 on Monday after an independent DMC recommended suspending enrollment in a Phase II/III trial of V710 to prevent Staphylococcus aureus infections following elective cardiothoracic...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

S: Phase II data

A double-blind, placebo-controlled, U.S. Phase II trial in 201 patients with end-stage renal disease (ESRD) undergoing hemodialysis showed that single and multiple dose regimens of V710 were well tolerated with no vaccine-related serious adverse events...
07:00 , Oct 7, 2010 |  BC Innovations  |  Targets & Mechanisms

Getting to the essence of Staph

Two recent studies from The University of Chicago have identified vaccine candidates to prevent Staphylococcus aureus infection. 1,2 The researchers think their strategy of targeting essential surface-localized virulence factors could generate better results than current...